CSF3 and sarcopenia: 28 (25.0%) patients treated with short-acting granulocyte colony stimulating factor, the WBC count rebounded enough to tolerate the next cycle of T + GC, and three patients with sarcopenia permanently discontinued therapy due to severe leukopenia.